Sara Baker says the light went on in her head after a cup of hot cocoa set off a storm in her stomach.
“I went back and looked at the package and there it was: carrageenan,” said Baker, a career services coordinator from Bloomington in central Illinois.
Baker been taking medication for ulcerative colitis for years but still suffered debilitating digestive flare-ups without warning. She had read warnings about carrageenan in a natural health newsletter but didn’t take them seriously.
This time, though, “it really clicked,” she said of the ingredient, which researchers say has not been conclusively linked to gastrointestinal problems in humans. “It took awhile to learn just how many things it’s in, but now that know, I can avoid it and I no longer have the problems.”
Experiences like Baker’s have led some people with gastrointestinal problems to sidestep mainstream medical advice and avoid carrageenan, a seaweed-derived texturizer found in meat, dairy and other processed foods — including some organic products.
For scientists, however, these are just anecdotes. Though studies on lab animals and human cells have suggested that carrageenan can cause gastrointestinal inflammation, many researchers and physicians say it’s unclear whether it has the same impact on people who consume it.
Scientists at the University of Illinois at Chicago and University of Chicago are seeking to address that question with a controlled clinical trial that Baker is participating in.
“I believe it’s worth investigating and doing the science to find out,” said Dr. Stephen Hanauer, a medical professor and chief of gastroenterology and nutrition at University of Chicago Medicine.
His co-researcher, UIC physician and professor Joanne Tobacman, has been looking at the health effects of carrageenan for more than a decade and is concerned enough to have petitioned the U.S. Food and Drug Administration in 2008 to prohibit the use of carrageenan in food.
Her petition cited decades of publicly funded, peer-reviewed science — including her own — on carrageenan-induced inflammation in animals and cells. In June 2012, the FDA responded with a letter of denial.
“It was disappointing that with such clear evidence about the effects of carrageenan on inflammation, the FDA did not restrict the use of carrageenan, particularly in infant formula,” Tobacman said. Europe does not allow the ingredient in formula.
The additive, which lends a uniform, creamy texture to food, can be found in soy milk, yogurt, ice cream, cheeses, some meats, diet soft drinks and even toothpaste.
Michael Adams, deputy director of the FDA’s Office of Food Additive Safety, said the petition did not make a compelling case to re-examine the safety of carrageenan. “It has been reviewed repeatedly by FDA scientists and other international organizations, and in the judgment of those experts there hasn’t been a problem,” he said.
Adams called a rat study from 2006 “the gold standard for us because it exactly mimics the exposure consumers are going to get when they eat these carrageenan-containing foods.”
That study was funded and performed by a manufacturer of carrageenan. Adams said he didn’t know that but added: “If you look at the science and you believe it’s well done it doesn’t matter where the money comes from.”
Many gastroenterologists are not convinced carrageenan is dangerous.
“There are some studies in rats and mice showing that carrageenan exposure can lead to GI inflammation that mimics things like Crohn’s” disease, said Dr. Sunanda Kane, a Mayo Clinic physician and medical adviser to the Crohn’s and Colitis Foundation of America. “But it’s never been shown on human tissue in humans walking around.”
Over the last 50 years, incidence of inflammatory bowel disease has risen as people eat more processed food, Kane said. “But is it carrageenan or that we don’t exercise or have lots of other additives and preservatives or fructose in our food supply?”
In Hanauer and Tobacman’s study, people whose ulcerative colitis is in remission are being put on a carrageenan-free diet, then given either a controlled dose of carrageenan or a placebo.
So far, the research has been hampered by low volunteer rates — currently, fewer than 20 subjects. Hanauer notes that the prospect of re-inflaming one’s inactive ulcerative colitis is not particularly attractive.
But Baker, who was one of more than 120 people who responded when Cornucopia asked to hear from those with carrageenan-related digestive problems, said she was willing to go through it to help establish human science on the topic.
“I believe there are people who are as sick as I was, or even worse, who need this information,” she said.
About the Author
